About Jace Biomedical
JBI is a small but growing pharmaceutical company with a focus on developing novel therapies for the treatment of AD. Two veterans of the pharmaceutical industry, Carl Horn and Deborah Milkowski, PhD, founded JBI.
JBI’s approach to discovering new drugs for AD is based on research performed in the lab of Luigi Puglielli, MD, PhD, over the last eight years at the University of Wisconsin-Madison. Dr. Puglielli now focuses his research at UW to further elucidating (1) the cellular mechanisms within neurons that lead to the biochemical hallmarks of AD progression and (2) the cell’s remarkable ability to designate or “mark” a protein as having passed “quality control” for transport out of the endoplasmic reticulum. These discoveries have profound implications for neurodegenerative disease management.
After working together for several years at TAP Pharmaceuticals strategically building its pipeline, Mr. Horn and Dr. Milkowski once again joined forces in early 2013 and began collaborative discussions with Dr. Puglielli to explore the potential of translating his novel research into a groundbreaking treatment for tens of millions of AD patients. By mid-2014, JBI was founded as a Midwest biotech.